구독하기
연구 모델
서비스
전임상 효능 평가
Resource
NKG-H11-hB2M&HLA-A2.1 Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
NKG-H11-hB2M&HLA-A2.1 Mouse
제품명
NKG-H11-hB2M&HLA-A2.1 Mouse
제품 ID
C001844
품종 계통
NOD.Cg-PrkdcscidIl2rgem1cyaIgs2em1(B2M/HLA-A2.1/H2-D1)/Cya
Backgroud
NKG
상태
이 마우스 계통을 논문에서 사용할 경우, “NKG-H11-hB2M&HLA-A2.1 Mouse (카탈로그 번호 C001844)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Immunodeficient Mice
Safe Harbor Knock-in
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Immunodeficient Mice
Safe Harbor Knock-in
기본 정보
관련 자료
기본 정보
유전자 별칭
IMD43, HLAA, gc, p64, [g]c, CD132, gamma(c)
염색체
Chr 15, Chr 6, Chr X
MGI ID
Datasheet
품종 계통 설명
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3].
NKG-H11-hB2M&HLA-A2.1 mouse is a model constructed via gene editing technology, in which the H2-K1 chimeric HLA-A2.1 gene is knocked into the H11 locus of mice on the NKG strain background. Compared with NKG mice, NKG-H11-hB2M&HLA-A2.1 mice generate functional human T cell subsets with HLA-restricted immune responses after hematopoietic stem cell (HSC) transplantation. Human cytotoxic T lymphocytes (CTLs) developed in immunologically reconstituted mice recognize pathogens in an HLA-restricted manner and exert HLA-restricted cytotoxicity against infected human B cells [4]. This model provides an ideal platform for investigating human immune responses to pathogens, HLA-restricted cytotoxic responses, and related research areas.
Reference
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002 Nov 15;100(10):3681-9.
Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K(b) transgenic mice. Int J Cancer. 2002 Aug 10;100(5):565-70.
Boucherma R, Kridane-Miledi H, Bouziat R, Rasmussen M, Gatard T, Langa-Vives F, Lemercier B, Lim A, Bérard M, Benmohamed L, Buus S, Rooke R, Lemonnier FA. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol. 2013 Jul 15;191(2):583-93.
Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7.
변형 전략
The Mouse K2-K1 promoter-Kozak-HLA-A2.1 leader sequence - Human Mature B2M CDS-3xGGGGS-Chimeric-HLA-A2.1 (HLA-A2.1 alpha1 and alpha2 binding domains-H2-D1 alpha3, cytoplasmic and transmembrane domains)-H2-D1 3'sequence cassette was inserted into H11 locus.

Figure 1. Gene editing strategy of NKG-H11-hB2M&HLA-A2.1 mice.
응용 분야
Construction of immune system humanized mouse models;
Research on the human immune system and hematopoietic system;
Research on HLA-restricted cytotoxic responses, research on human viral infectious diseases, and development and testing of novel viral vaccines;
Research on oncology and autoimmune diseases;
Cell line-derived xenograft (CDX) and drug screening and efficacy evaluation;
Patient-derived xenograft (PDX) and drug screening and efficacy evaluation.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
